TAS-106

Generic Name: TAS-106

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₃N_₃O_₅

CAS Number: 180300-43-0

Unique Ingredient Identifier: Y3O05I09ZK

Background: TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours .

Indication: Investigated for use/treatment in solid tumors and cancer/tumors (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase I Study of TAS-106 in Combo With Carboplatin

Phase 1

Completed

Conditions: Cancer
Solid Tumors

Interventions: Drug: TAS-106
Drug: Carboplatin

First Posted Date: 2008-09-12

Last Posted Date: 2012-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT00752011

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of TAS-106 to Treat Head and Neck Cancer

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: TAS-106

First Posted Date: 2008-08-19

Last Posted Date: 2012-09-05

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 27

Registration Number: NCT00737360

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Orleans Street, Baltimore, Maryland, United States
🇸🇬
National University Hospital, Lower Kent Ridge Road, Singapore
🇨🇳
National Taiwan University Hospital Department of Oncology, No. 1, Chang-De Street , Taipei, Taiwan

and more 2 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy